A Young Biotech Firm’s Dilemma
Should publicly held, early stage biotechs issue more shares or partner with Big Pharma?
Should publicly held, early stage biotechs issue more shares or partner with Big Pharma?
ABOUT FORTUNA ADVISORS
Our team has advised hundreds of clients on developing a new approach to creating exceptional value for stakeholders and shareholders. Our differentiated cash-based earnings approach to strategic management and capital allocation draws on years of experience as advisors and investors at Credit Suisse, Morgan Stanley, Lehman Brothers, DLJ, Stern Stewart, Marakon, Ernst & Young, and ISS.
© 2021 FORTUNA ADVISORS – ALL RIGHTS RESERVED